New IPO news | Chengdu Olymvax Biopharmaceuticals Inc (688319.SH) submits a second application to the Hong Kong Stock Exchange.

According to the disclosure on June 30th by the Hong Kong Stock Exchange, Chengdu Olymvax Biopharmaceuticals Inc (referred to as Chengdu Olymvax Biopharmaceuticals Inc, 688319.SH) submitted an application to the Main Board of the Hong Kong Stock Exchange for listing. This is the second time the company has submitted an application to the Hong Kong Stock Exchange, with CITIC SEC as its exclusive sponsor. The prospectus shows that Chengdu Olymvax Biopharmaceuticals Inc is a biopharmaceutical company dedicated to the research, development, production, and commercialization of innovative vaccines. The company has built a systematic product development framework, focusing on key research and development areas and managing research and development projects at different stages of development. The company's strategic focus is on two core areas: "superbacterial vaccines" and "adult vaccines." Since its establishment, Chengdu Olymvax Biopharmaceuticals Inc has built a comprehensive production and quality management system, and has established a broad sales network covering 30 provinces, municipalities, and autonomous regions in China.